Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. More Details
No risks detected for HRMY from our risk checks.
High growth potential with mediocre balance sheet.
Share Price & News
How has Harmony Biosciences Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HRMY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: HRMY's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how HRMY performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how HRMY performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Harmony Biosciences Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHarmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) About To Shift From Loss To Profit
4 months ago | Simply Wall StHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY): When Will It Breakeven?
Is Harmony Biosciences Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HRMY ($28.28) is trading below our estimate of fair value ($180.88)
Significantly Below Fair Value: HRMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HRMY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: HRMY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HRMY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HRMY is overvalued based on its PB Ratio (16.6x) compared to the US Pharmaceuticals industry average (3.8x).
How is Harmony Biosciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HRMY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: HRMY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HRMY's is expected to become profitable in the next 3 years.
Revenue vs Market: HRMY's revenue (28.9% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: HRMY's revenue (28.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HRMY's Return on Equity is forecast to be high in 3 years time
How has Harmony Biosciences Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: HRMY is currently unprofitable.
Growing Profit Margin: HRMY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HRMY's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare HRMY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HRMY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).
Return on Equity
High ROE: HRMY has a negative Return on Equity (-38.02%), as it is currently unprofitable.
How is Harmony Biosciences Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: HRMY's short term assets ($262.9M) exceed its short term liabilities ($134.5M).
Long Term Liabilities: HRMY's short term assets ($262.9M) exceed its long term liabilities ($195.4M).
Debt to Equity History and Analysis
Debt Level: HRMY's debt to equity ratio (199.9%) is considered high.
Reducing Debt: Insufficient data to determine if HRMY's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HRMY has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HRMY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Harmony Biosciences Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HRMY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HRMY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HRMY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HRMY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HRMY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Jacobs (52 yo)
Mr. John Charles Jacobs, MBA, serves as President and Chief Executive Officer of Harmony Biosciences, LLC. He served as Chairman of Harmony Biosciences, LLC.., since 2019 until March 2020. He serves as Pre...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD845.66K) is below average for companies of similar size in the US market ($USD1.56M).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
Experienced Management: HRMY's management team is considered experienced (2.3 years average tenure).
Experienced Board: HRMY's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: HRMY only recently listed within the past 12 months.
Harmony Biosciences Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Harmony Biosciences Holdings, Inc.
- Ticker: HRMY
- Exchange: NasdaqGM
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$419.788m
- Shares outstanding: 56.89m
- Website: https://www.harmonybiosciences.com
Number of Employees
- Harmony Biosciences Holdings, Inc.
- 630 West Germantown Pike
- Suite 215
- Plymouth Meeting
- United States
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for th...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/16 23:47|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.